Diabetes research and clinical practice

Views on Weight Control in Diabetes Using Survodutide

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Survodutide, a novel dual GCGR/GLP-1R agonist, has shown glucose-lowering efficacy and clinically meaningful body weight loss in a Phase II trial.

  • Survodutide is a 29-amino acid peptide derived from glucagon, designed to mimic the natural gut hormone oxyntomodulin.
  • The incorporation of a C18 diacid allows for binding to albumin, which prolongs the drug's half-life for once-weekly dosing.
  • GCGR agonism in survodutide may enhance body weight loss by increasing energy expenditure alongside the appetite-reducing effects of GLP-1R agonists.
  • The treatment has been demonstrated to effectively reduce glycated hemoglobin levels in patients with Type 2 diabetes mellitus and obesity.
  • Dual GCGR/GLP-1R agonism could provide greater therapeutic benefits compared to GLP-1R agonism alone.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declaration of Competing Interest The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. Thomas Klein, Robert Augustin and Anita M. Hennige are employees of Boehringer Ingelheim.
PubMed

Related papers

Apr '24
Biomarkers and drug effects of survodutide, a medicine targeting two hormone receptors, for choosing clinical use
top 5% journal
cited by 12 papers
research support, non-u.s. gov't
Nov '22
BI 456906: Discovery and early testing of a new drug that targets two hormone receptors to strongly reduce obesity
top 5% journal
cited by 118 papers
research support, non-u.s. gov't
May '21
Partial activation improves blood sugar control by a hormone-based treatment targeting two related receptors
top 5% journal
cited by 15 papers
research support, non-u.s. gov't
Jul '09
Activating both GLP-1 and glucagon receptors reverses obesity in mice
top 5% journal
cited by 372 papers
journal article
Jan '23
New developments in peptide treatments for type 2 diabetes and obesity
cited by 90 papers
journal article
Jul '21
Long-Lasting Modified Frog GLP-1 Compounds That Activate Both GLP-1 and Glucagon Receptors to Treat Metabolic Disease
top 20% journal
cited by 9 papers
research support, non-u.s. gov't
Jul '18
Combined Effects of Glucagon and GLP-1 Drugs in Obese Diabetic Monkeys
top 10% journal
cited by 22 papers
research support, non-u.s. gov't
Jan '23
Discovery of new drugs that activate both blood sugar control and appetite regulation receptors
cited by 2 papers
research support, non-u.s. gov't
Jun '24
Using glucagon to treat metabolic diseases like type 2 diabetes and obesity
top 5% journal
cited by 30 papers
journal article
May '16
Treating diabetes and obesity by activating two hormone receptors called 'twincretins'
cited by 53 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
today7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
1 week ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
2 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
3 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
4 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
5 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
6 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
7 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
8 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief